


Sinopharm Shyndec passes clean production inspection

03 December 2012 | Regulatory | By BioSpectrum Bureau



Singapore: The Pudong base of Shanghai Shyndec Pharmaceutical (Sinopharm Shyndec) in China received clearance from an inspection team assessing the cleaner production plan implementation. The inspection was carried out by Shanghai Cleaner Production Center with authorization of Shanghai Environment Management Bureau.

Sinopharm or China National Pharmaceutical Group Corporation is the largest medical and healthcare group in China which is directly managed by State-owned Assets Supervision and Administration Commission of the State Council. Shanghai Shyndec Pharmaceutical is one of the five listed companies owned by Sinopharm.

The inspection team comprised professors and experts from East China University of Science and Technology, Shanghai Institute of Technology, Environment Management Bureau of Pudong New Area and Environmental Protection Association of Shanghai Pudong New Area among others.

The team reviewed the documents and did an on-site inspection to assess and validate the implementation results of a cleaner production plan. The inspection team unanimously approved Sinopharm Shyndec, making it the first to pass the new standards inspection in Shanghai.

Sinopharm Shyndec is among the first batch of key enterprises that applied for cleaner production inspection in 2011. The entire process of the inspection took one and a half years and 21 specific steps in seven inspection stages, including preliminary review, primary assessment as well as acceptance check. A working team at Pudong base was set up to collaborate with the leading team of the company to fully implement the cleaner production.

By consolidating the organization system, personnel training and improving hardware and facilities, the company finally met the requirements of being "energy saving, consumption reducing, pollution decreasing, and synergy enhancing" production unit.